Avalyn Pharma Inc. Common Stock (AVLN) vs Damora Therapeutics, Inc. (DMRA)
A side-by-side comparison of Avalyn Pharma Inc. Common Stock and Damora Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVLN
Avalyn Pharma Inc. Common Stock
$25.94HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
DMRA
Damora Therapeutics, Inc.
$18.94HealthcareDelayed quote: Oct 6, 2026, 11:55 AM EDT
Total return — AVLN vs DMRA
growth of $100 · dividends reinvested · last 1yAVLN -8.3% (-8.3%/yr)DMRA -21.2% (-21.2%/yr)AVLN compounded faster over this window
AVLN DMRA
AVLN vs DMRA: by the numbers
- •DMRA is the larger company ($1.17B vs $1.15B market cap).
Metrics side by side
Valuation
| Metric | AVLN | DMRA |
|---|---|---|
| P/B ratio | 2.89 | 3.02 |
Profitability
| Metric | AVLN | DMRA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | N/A | -50.93% |
| ROIC | -67.73% | -52.44% |
Growth (annualized)
| Metric | AVLN | DMRA |
|---|---|---|
| Total return CAGR (5Y) | N/A | -25.05% |
Go deeper
Dig into the metrics
Avalyn Pharma Inc. Common Stock ROEDamora Therapeutics ROEAvalyn Pharma Inc. Common Stock operating marginDamora Therapeutics operating marginAvalyn Pharma Inc. Common Stock revenue growthDamora Therapeutics revenue growthAvalyn Pharma Inc. Common Stock free cash flowDamora Therapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.